Exhibitor Info        Why Exhibit?
Current Exhibitors: Winter Meeting        Summer Meeting
Past Exhibitors: Winter Meeting        Summer Meeting

2018 Summer Meeting
Omni Amelia Island Plantation
Amelia Island, FL
August 3 - 4, 2018

Descriptions and more information from our exhibitors can be found below.
Please take the time to review the information.

Gold Level

Janssen Pharmaceuticals


Professional Risk Management Services


Sunovion Pharmaceuticals Inc.

Silver Level

Alpha Genomix Laboratory


Neurocrine


Takeda Pharmaceuticals U.S.A., Inc. & Lundbeck

Exhibitors
Alliant Quality
Hopeway
MHM Services
Ridgeview Institute
Skyland Trail
Syneos Health / Merck
Veritas Collaborative
WellStar Health System

Company Name Booth #
Alliant Quality
Alpha Genomix Laboratory 29
Hopeway
Janssen Pharmaceuticals
MHM Services

MHM Services, Inc. is a leading provider of comprehensive healthcare services to correctional facilities, state psychiatric hospitals, and community mental health center nationwide.  We have provided exceptional mental health services to the Georgia Department of Corrections for 20 years, and proud to now provide these services to the West Central Georgia Regional Hospital.

Neurocrine
Professional Risk Management Services

Professional Risk Management Services, Inc.® specializes in medical professional liability insurance for individual healthcare providers, group practices, facilities, associations and organizations.  As a national company, we develop, deliver and implement customized programs and services, including unparalleled risk management, proven defense strategies and specialized policies. Our impressive 95% retention rate illustrates our dedication to client relationships and satisfaction, the quality of service we provide, and the skill and responsiveness of our staff. Administrative defense coverage of $50,000 is included. Coverage for telepsychiatry and forensic services is included. Premium discounts up to 60% are available.
May vary by state.

Ridgeview Institute
Skyland Trail
LOCATED IN ATLANTA, Skyland Trail is a nonprofit mental health treatment organization serving adults ages 18 and older with a primary psychiatric diagnosis. Through our residential and day treatment programs, we help our clients grow, recover, and reclaim their lives. We offer expert, evidence-based psychiatric treatment alongside a compassionate, holistic path to wellness. Specialized treatment teams include Young Adults with First Episode Psychosis, CBT, DBT, and Social Integration. Many clients participate in our Dual Diagnosis program as a second area of focus. Unique therapies offered include music, art and horticultural therapy; vocational services; primary care; family therapy; and healthy living.
Sunovion Pharmaceuticals Inc.
Syneos Health / Merck

BELSOMRA (suvorexant) 5, 10, 15, 20 mg tablets
Belsomra is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

  • Belsomra is contraindicated in patients with narcolepsy. 
  • Belsomra contains suvorexant, a Schedule IV controlled substance.
  • Belsomra can impair daytime wakefulness. Central nervous system (CNS) depressant effects can last for up to several days after discontinuation.

There are 2 pathways in your brain – a wake and a sleep pathway.  Both wake and sleep pathways can play a role in Insomnia.  Belsomra is thought to help
Quiet the wake pathway, by targeting and inhibiting the action of orexin.  Orexin is a neurotransmitter that is the central promoter of wakefulness.
Belsomra is available in multiple strengths, so you can find the right dose for your patients. The recommended dose is 10 mg.  Only take Belsomra 1 time each night, if needed, within 30 minutes of going to bed and when you can get a full night’s sleep of at least 7 hours. Belsomra can be taken with or without a meal.
You can learn more by visiting belsomra.com
Please see the Prescribing Information for more information.

Takeda Pharmaceuticals U.S.A., Inc. & Lundbeck
Takeda Pharmaceuticals Company Limited and Lundbeck formed a strategic alliance in 2007 to co‐develop and co‐commercialize in the US and Japan several compounds in Lundbeck’s pipeline for the treatment of mood and anxiety disorders. Together, both companies are deeply committed to supporting the needs of the mental health community.
Veritas Collaborative
WellStar Health System

For any questions or more information please contact:

Matt Van Wie
Manager, Corporate & Educational Support
(804) 550-2312
(804) 550-0695 fax
matt@esvw.com